Faculty Collaboration Database

Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. Ann Surg Oncol 2013 Apr;20(4):1230-9

Date

10/16/2012

Pubmed ID

23064778

DOI

10.1245/s10434-012-2648-0

Scopus ID

2-s2.0-84875203659 (requires institutional sign-in at Scopus site)   9 Citations

Abstract

Neoadjuvant chemoradiation has demonstrated significant advantages in the management of pancreatic adenocarcinoma. A similar tumor in a nearby anatomical location is extrahepatic cholangiocarcinoma, which has proven to be largely unresponsive to current forms of therapy. Neoadjuvant therapy for hilar cholangiocarcinoma has been combined with surgical resection and/or liver transplantation with a 25-33 % complete pathological response rate. We propose a wider application of neoadjuvant chemoradiation for patients with distal cholangiocarcinoma and present our rationale for this form of treatment sequencing.

Author List

Turaga KK, Tsai S, Wiebe LA, Evans DB, Gamblin TC

Authors

Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of Wisconsin
Thomas Clark Gamblin MD Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antimetabolites, Antineoplastic
Bile Duct Neoplasms
Bile Ducts, Intrahepatic
Brachytherapy
Cholangiocarcinoma
Combined Modality Therapy
Fluorouracil
Humans
Liver Transplantation
Neoadjuvant Therapy
Neoplasm Staging
Postoperative Complications
Prognosis
Survival Rate